SCHEMBL24373532

SCHEMBL24373532

Cc1cc(O)cc(C=O)c1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.60
CHRM1 P11229 1/20 0.60
ALOX15 P16050 1/20 0.60
MAOA P21397 1/20 0.60
TBXA2R P21731 1/20 0.60
ADRA1A P35348 1/20 0.60
HTR2B P41595 1/20 0.60
ERN1 O75460 7/20 0.43
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
TRIM24 O15164 1/20 0.36
TYR P14679 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
MPI P34949 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748873 0.78 ERN1 (0.47) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL3469126 0.78 ERN1 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL29952878 0.78 ERN1 (0.52) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL209613 0.78 ERN1 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
Chloroxylenol SCHEMBL7950378 0.77 CYP3A4 (1.00) CYP3A4CHRM1ALOX15MAOATBXA2R
Chloroxylenol SCHEMBL34163 0.77 CYP3A4 (1.00) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL28608059 0.75 ERN1 (0.50) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL15783650 0.75 ERN1 (0.48) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL31648883 0.75 ERN1 (0.44) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL25612184 0.75 ERN1 (0.43) CYP3A4CHRM1ALOX15MAOATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 US disclosed
EP-4232444-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2023-08-30 EP disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 WO disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC CYP3A4 3478/4885CHRM1 4856/4885ALOX15 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.